Johnson & Johnson’s Rybrevant is on the brink of EU approval as a treatment for a subset of patients with newly diagnosed EGFR-positive lung cancer ... last year after a trial that was supposed ...

Treatment resistance and relapse in the most common type of lung cancer can be traced to a protein called agrin, according to ...

The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 ...

Electronic "nose" analysis of exhaled breath achieved 80-90% accuracy for detecting lung cancer in patients with suspicious ...

Researchers from Touro University and Lovelace Biomedical are Developing an Innovative Treatment for Lung Cancer ...

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Lung cancer screening with low-dose CT could have saved tens of thousands of lives — if only we'd listened to the data back ...

Researchers have discovered that 'DEAD-box helicases 54 (DDX54)', a type of RNA-binding protein, is the master regulator that hinders the effectiveness of immunotherapy -- opening a new path for lung ...

Candel Therapeutics has identified a subpopulation of lung cancer patients living longest on its oncolytic virus, leading the biotech to narrow its focus as it heads towards a potentially ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

“Imfinzi has helped change the treatment landscape and achieved multiple positive phase 3 trials for patients with earlier stages of lung cancer,” she added. “We are committed to addressing ...